Before revision: In September 2012, the FDA published its strategy for improved postmarket surveillance based in part on the discussions from the IDEAL meeting, including the promotion of registries for devices, better assessment of evidence already published, and improved reporting of adverse URL
After revision: In September 2012, the FDA published its strategy for improved postmarket surveillance based in part on the discussions from the IDEAL meeting, including the promotion of registries for devices, better assessment of evidence already published, and improved reporting of adverse events .